BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19375649)

  • 1. Expression of the adaptor protein Lnk in leukemia cells.
    Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
    Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
    Simon C; Dondi E; Chaix A; de Sepulveda P; Kubiseski TJ; Varin-Blank N; Velazquez L
    Blood; 2008 Nov; 112(10):4039-47. PubMed ID: 18753636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit.
    Sun J; Pedersen M; Rönnstrand L
    J Biol Chem; 2008 Oct; 283(41):27444-27451. PubMed ID: 18697750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.
    Tong W; Lodish HF
    J Exp Med; 2004 Sep; 200(5):569-80. PubMed ID: 15337790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.
    Lin DC; Yin T; Koren-Michowitz M; Ding LW; Gueller S; Gery S; Tabayashi T; Bergholz U; Kazi JU; Rönnstrand L; Stocking C; Koeffler HP
    Blood; 2012 Oct; 120(16):3310-7. PubMed ID: 22942183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptor protein Lnk associates with Tyr(568) in c-Kit.
    Gueller S; Gery S; Nowak V; Liu L; Serve H; Koeffler HP
    Biochem J; 2008 Oct; 415(2):241-5. PubMed ID: 18588518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.
    Looi CY; Imanishi M; Takaki S; Sato M; Chiba N; Sasahara Y; Futaki S; Tsuchiya S; Kumaki S
    PLoS One; 2011; 6(8):e23640. PubMed ID: 21853157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
    Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
    J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
    Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
    Bersenev A; Wu C; Balcerek J; Tong W
    J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
    Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
    J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppressor activity of SOCS-1.
    Rottapel R; Ilangumaran S; Neale C; La Rose J; Ho JM; Nguyen MH; Barber D; Dubreuil P; de Sepulveda P
    Oncogene; 2002 Jun; 21(28):4351-62. PubMed ID: 12080466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
    Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
    J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
    Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
    Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.